| Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus … EJ Small, M Meyer, ME Marshall, LM Reyno, FJ Meyers, RB Natale, ... Journal of clinical oncology 18 (7), 1440-1450, 2000 | 217 | 2000 |
| Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer LF Allen, PF Lenehan, IA Eiseman, WL Elliott, DW Fry Seminars in oncology 29 (3), 11-21, 2002 | 144 | 2002 |
| CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer LF Allen, IA Eiseman, DW Fry, PF Lenehan Seminars in oncology 30, 65-78, 2003 | 139 | 2003 |
| Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non–small-cell lung cancer PA Jänne, J von Pawel, RB Cohen, L Crino, CA Butts, SS Olson, ... Journal of clinical oncology 25 (25), 3936-3944, 2007 | 135 | 2007 |
| Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer S Campos, O Hamid, MV Seiden, A Oza, M Plante, RK Potkul, ... Journal of Clinical Oncology 23 (24), 5597-5604, 2005 | 129 | 2005 |
| Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study E Calvo, AW Tolcher, LA Hammond, A Patnaik, JS de Bono, IA Eiseman, ... Clinical Cancer Research 10 (21), 7112-7120, 2004 | 117 | 2004 |
| Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end … EJ Small, A McMillan, M Meyer, L Chen, WJ Slichenmyer, PF Lenehan, ... Journal of clinical oncology 19 (5), 1304-1311, 2001 | 89 | 2001 |
| Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer J Nemunaitis, I Eiseman, C Cunningham, N Senzer, A Williams, ... Clinical cancer research 11 (10), 3846-3853, 2005 | 88 | 2005 |
| The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer AP Mitra, AA Almal, B George, DW Fry, PF Lenehan, V Pagliarulo, ... BMC cancer 6, 1-16, 2006 | 84 | 2006 |
| A phase I clinical and biomarker study of CI-1033, a novel pan-erbB tyrosine kinase inhibitor in patients with solid tumors DM Shin, J Nemunaitis, RG Zinner, NJ Donato, H Shin, JN Myers, ... Proc Am Soc Clin Oncol 20, 82a, 2001 | 79 | 2001 |
| Intestinal mucosa remodeling by recombinant human epidermal growth factor1-48 in neonates with severe necrotizing enterocolitis PB Sullivan, PJ Lewindon, C Cheng, PF Lenehan, K Bo-Sheng, ... Journal of pediatric surgery 42 (3), 462-469, 2007 | 68 | 2007 |
| Use of artificial intelligence and machine learning algorithms with gene expression profiling to predict recurrent nonmuscle invasive urothelial carcinoma of the bladder G Bartsch Jr, AP Mitra, SA Mitra, AA Almal, KE Steven, DG Skinner, ... The Journal of urology 195 (2), 493-498, 2016 | 61 | 2016 |
| A phase I clinical and pharmacokinetic study of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors JJ Rinehart, G Wilding, J Willson, S Krishnamurthi, R Natale, S Mani, ... Proc Am Soc Clin Oncol 21 (Suppl 1), 11a, 2002 | 50 | 2002 |
| Generation and external validation of a tumor‐derived 5‐gene prognostic signature for recurrence of lymph node‐negative, invasive colorectal carcinoma PF Lenehan, LA Boardman, D Riegert‐Johnson, G De Petris, DW Fry, ... Cancer 118 (21), 5234-5244, 2012 | 46 | 2012 |
| A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors LL Garland, M Hidalgo, DS Mendelson, DP Ryan, BK Arun, JL Lovalvo, ... Clinical cancer research 12 (14), 4274-4282, 2006 | 42 | 2006 |
| Resistance to oxidants associated with elevated catalase activity in HL-60 leukemia cells that overexpress multidrug-resistance protein does not contribute to the resistance to … PF Lenehan, PL Gutiérrez, JL Wagner, N Milak, GR Fisher, DD Ross Cancer chemotherapy and pharmacology 35 (5), 377-386, 1995 | 41 | 1995 |
| Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer RG Zinner, J Nemunaitis, I Eiseman, HJC Shin, SC Olson, J Christensen, ... Clinical cancer research 13 (10), 3006-3014, 2007 | 38 | 2007 |
| Superiority of suramin+ hydrocortisone over placebo+ hydrocortisone: results of a multi-center double-blind phase III study in patients with hormone refractory prostate cancer EJ Small, ME Marshall, L Reyno, F Meyers, R Natale, M Meyer, ... PROCEEDINGS OF THE ANNUAL MEETING-AMERICAN SOCIETY OF CLINICAL ONCOLOGY 17 …, 1998 | 37 | 1998 |
| A phase I clinical and biomarker study of the novel pan-erbB tyrosine kinase inhibitor, CI-1033, in patients with solid tumors RG Zinner, JJ Nemunaitis, NJ Donato, HC Shin, JN Myers, PS Zhang, ... Clin Cancer Res 7 (Suppl), 566, 2001 | 29 | 2001 |
| Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study GR Simon, CR Garrett, SC Olson, M Langevin, IA Eiseman, JJ Mahany, ... Clinical cancer research 12 (15), 4645-4651, 2006 | 26 | 2006 |
